JPMorgan Forecast Over 85% Upside for Two Biopharma Stocks Targeting Obesity and Chronic Conditions
This year’s steady climb of the S&P 500 index has market experts forecasting a robust remainder of 2024. JPMorgan analyst Madison Faller recently highlighted that the S&P 500 has gained over 10% in 100 trading days, and whenever that has happened since 1950, “stocks have closed out the full year with an average return of … Read more
